U Helena Danielson

List of Publications by Year
in descending order

144 papers	7,119 citations	71102 41 h-index	62596 80 g-index
152 all docs	152 docs citations	152 times ranked	6543 citing authors

#	Article	IF	Citations
1	Glutathione Transferasesâ€"Structure and Catalytic Activit. Critical Reviews in Biochemistry, 1988, 23, 283-337.	7.5	1,595
2	4-Hydroxyalk-2-enals are substrates for glutathione transferase. FEBS Letters, 1985, 179, 267-270.	2.8	391
3	Biophysics in drug discovery: impact, challenges and opportunities. Nature Reviews Drug Discovery, 2016, 15, 679-698.	46.4	285
4	Isothiocyanates as substrates for human glutathione transferases: structure-activity studies. Biochemical Journal, 1995, 311, 453-459.	3.7	234
5	Structure-activity relationships of 4-hydroxyalkenals in the conjugation catalysed by mammalian glutathione transferases. Biochemical Journal, 1987, 247, 707-713.	3.7	161
6	Cyclic HIV-1 Protease Inhibitors Derived from Mannitol:Â Synthesis, Inhibitory Potencies, and Computational Predictions of Binding Affinities. Journal of Medicinal Chemistry, 1997, 40, 885-897.	6.4	158
7	Relationships between Structure and Interaction Kinetics for HIV-1 Protease Inhibitors. Journal of Medicinal Chemistry, 2002, 45, 5430-5439.	6.4	140
8	Purification of major basic glutathione transferase isoenzymes from rat liver by use of affinity chromatography and fast protein liquid chromatofocusing. Analytical Biochemistry, 1985, 146, 313-320.	2.4	131
9	Kinetic independence of the subunits of cytosolic glutathione transferase from the rat. Biochemical Journal, 1985, 231, 263-267.	3.7	126
10	Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses. Journal of the American Chemical Society, 2022, 144, 2905-2920.	13.7	118
11	Development of a Radiochemical Cyclooxygenase-1 and -2 in Vitro Assay for Identification of Natural Products as Inhibitors of Prostaglandin Biosynthesis. Journal of Natural Products, 1998, 61, 2-7.	3.0	110
12	Expression of class Pi glutathione transferase in human malignant melanoma cells. Carcinogenesis, 1987, 8, 1929-1932.	2.8	104
13	Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the Î±7 nicotinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2543-52.	7.1	102
14	Synthesis and Comparative Molecular Field Analysis (CoMFA) of Symmetric and Nonsymmetric Cyclic Sulfamide HIV-1 Protease Inhibitors. Journal of Medicinal Chemistry, 2001, 44, 155-169.	6.4	101
15	Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (Protease-Helicase/NTPase): A comparative study of different C-terminals. Bioorganic and Medicinal Chemistry, 2003, 11, 2551-2568.	3.0	99
16	Proximity-dependent initiation of hybridization chain reaction. Nature Communications, 2015, 6, 7294.	12.8	88
17	Identification and Characterization of an Irreversible Inhibitor of CDK2. Chemistry and Biology, 2015, 22, 1159-1164.	6.0	85
18	A Protein Interaction Node at the Neurotransmitter Release Site: Domains of Aczonin/Piccolo, Bassoon, CAST, and Rim Converge on the N-Terminal Domain of Munc13-1. Journal of Neuroscience, 2009, 29, 12584-12596.	3.6	77

#	Article	IF	Citations
19	Screening of Compounds Interacting with HIV-1 Proteinase Using Optical Biosensor Technology. Analytical Biochemistry, 1998, 265, 340-350.	2.4	76
20	Design and Fast Synthesis of C-Terminal Duplicated PotentC2-Symmetric P1/P1â€˜-Modified HIV-1 Protease Inhibitors. Journal of Medicinal Chemistry, 1999, 42, 3835-3844.	6.4	75
21	Structural basis of ligand recognition in 5â€HT₃ receptors. EMBO Reports, 2013, 14, 49-56.	4.5	74
22	Kinetic Analysis of the Interaction between HIV-1 Protease and Inhibitors Using Optical Biosensor Technology. Analytical Biochemistry, 2000, 279, 71-78.	2.4	73
23	Design and Synthesis of New PotentC2-Symmetric HIV-1 Protease Inhibitors. Use ofl-Mannaric Acid as a Peptidomimetic Scaffold. Journal of Medicinal Chemistry, 1998, 41, 3782-3792.	6.4	72
24	Fragment Library Screening and Lead Characterization Using SPR Biosensors. Current Topics in Medicinal Chemistry, 2009, 9, 1725-1735.	2.1	69
25	Structural and Functional Analysis of Hepatitis C Virus Strain JFH1 Polymerase. Journal of Virology, 2009, 83, 11926-11939.	3.4	68
26	Characterization of Ca2+ and phosphocholine interactions with C-reactive protein using a surface plasmon resonance biosensor. Analytical Biochemistry, 2009, 391, 39-44.	2.4	65
27	Determination of Interaction Kinetic Constants for HIV-1 Protease Inhibitors Using Optical Biosensor Technology. Analytical Biochemistry, 2001, 291, 207-218.	2.4	58
28	Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. Journal of Molecular Recognition, 2004, 17, 106-119.	2.1	57
29	Inhibitors of the C2-Symmetric HIV-1 Protease:â€‰ Nonsymmetric Binding of a Symmetric Cyclic Sulfamide with Ketoxime Groups in the P2/P2â€˜ Side Chains. Journal of Medicinal Chemistry, 1999, 42, 4054-4061.	6.4	53
30	Identification of MMP-12 Inhibitors by Using Biosensor-Based Screening of a Fragment Library. Journal of Medicinal Chemistry, 2008, 51, 3449-3459.	6.4	53
31	Structural Changes of Mercaptohexanol Self-Assembled Monolayers on Gold and Their Influence on Impedimetric Aptamer Sensors. Analytical Chemistry, 2019, 91, 14697-14704.	6.5	52
32	Effect of the Protonation State of the Titratable Residues on the Inhibitor Affinity to BACE-1. Biochemistry, 2010, 49, 7255-7263.	2.5	51
33	Expression and purification of recombinant full-length NS3 proteaseâ€“helicase from a new variant of Hepatitis C virus. Protein Expression and Purification, 2002, 25, 363-371.	1.3	48
34	Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants. Antiviral Research, 2003, 58, 235-242.	4.1	48
35	Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 1448-1474.	3.0	48
36	Interaction Kinetic Characterization of HIV-1 Reverse Transcriptase Non-nucleoside Inhibitor Resistance. Journal of Medicinal Chemistry, 2006, 49, 2375-2387.	6.4	47

#	Article	IF	Citations
37	Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3. Bioorganic and Medicinal Chemistry, 2006, 14, 544-559.	3.0	46
38	Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 4057-4068.	3.0	45
39	Proteolytic cleavage of microtubule-associated proteins by retroviral proteinases. Journal of General Virology, 1990, 71, 1985-1991.	2.9	44
40	Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs. Antimicrobial Agents and Chemotherapy, 1997, 41, 2383-2388.	3.2	43
41	The Versatile Nature of the 6-Aminoquinolone Scaffold: Identification of Submicromolar Hepatitis C Virus NS5B Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 1952-1963.	6.4	43
42	Characterization of a Set of HIV-1 Protease Inhibitors Using Binding Kinetics Data from a Biosensor-Based Screen. Journal of Biomolecular Screening, 2000, 5, 353-359.	2.6	42
43	Improved Structureâ^'Activity Relationship Analysis of HIV-1 Protease Inhibitors Using Interaction Kinetic Data. Journal of Medicinal Chemistry, 2004, 47, 5953-5961.	6.4	42
44	Identification of a Novel Scaffold for Allosteric Inhibition of Wild Type and Drug Resistant HIV-1 Reverse Transcriptase by Fragment Library Screening. Journal of Medicinal Chemistry, 2011, 54, 699-708.	6.4	41
45	Structure-Based Discovery of Pyrazolobenzothiazine Derivatives As Inhibitors of Hepatitis C Virus Replication. Journal of Medicinal Chemistry, 2013, 56, 2270-2282.	6.4	40
46	Tetrapeptides as potent protease inhibitors of hepatitis C virus full-Length NS3 (Protease-Helicase/NTPase). Bioorganic and Medicinal Chemistry, 2002, 10, 3915-3922.	3.0	38
47	Early Absorption and Distribution Analysis of Antitumor and Anti-AIDS Drugs:Â Lipid Membrane and Plasma Protein Interactions. Journal of Medicinal Chemistry, 2005, 48, 3536-3546.	6.4	37
48	Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process. Future Medicinal Chemistry, 2009, 1, 1399-1414.	2.3	37
49	Monitoring drugâ€"serum protein interactions for early ADME prediction through Surface Plasmon Resonance technology. Journal of Pharmaceutical and Biomedical Analysis, 2017, 144, 188-194.	2.8	37
50	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 203-206.	2.2	35
51	P1/P1â€² modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays. European Journal of Pharmaceutical Sciences, 2001, 13, 203-212.	4.0	33
52	Studies of substrate-induced conformational changes in human cytomegalovirus protease using optical biosensor technology. Analytical Biochemistry, 2004, 332, 203-214.	2.4	33
53	Biosensor-Based Kinetic Characterization of the Interaction between HIV-1 Reverse Transcriptase and Non-nucleoside Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 2367-2374.	6.4	33
54	Synthesis of enantiomerically pure cis and trans 2-aminocyclopentanecarboxylic acids. Use of proline replacements in potential HIV-protease inhibitors. Tetrahedron, 1997, 53, 7975-7984.	1.9	32

#	Article	IF	Citations
55	Surface Plasmon Resonance Biosensor Based Fragment Screening Using Acetylcholine Binding Protein Identifies Ligand Efficiency Hot Spots (LE Hot Spots) by Deconstruction of Nicotinic Acetylcholine Receptor Î±7 Ligands. Journal of Medicinal Chemistry, 2010, 53, 7192-7201.	6.4	32
56	Experimental Validation of a Fragment Library for Lead Discovery Using SPR Biosensor Technology. Journal of Biomolecular Screening, 2011, 16, 15-25.	2.6	31
57	Identification of Structuralâ€“Kinetic and Structuralâ€“Thermodynamic Relationships for Thrombin Inhibitors. Biochemistry, 2013, 52, 613-626.	2.5	30
58	Interaction Kinetic and Structural Dynamic Analysis of Ligand Binding to Acetylcholine-Binding Protein. Biochemistry, 2010, 49, 8143-8154.	2.5	28
59	On the Active Site Protonation State in Aspartic Proteases: Implications for Drug Design. Current Pharmaceutical Design, 2013, 19, 4257-4275.	1.9	28
60	A convenient synthesis of 1-(S)-[1â€²-(S)-(t-butyloxycarbonylamino)-2â€²-phenylethyl]oxirane. A useful building block in the synthesis of HIV protease inhibitors. Tetrahedron Letters, 1997, 38, 3483-3486.	1.4	27
61	Noelin1 Affects Lateral Mobility of Synaptic AMPA Receptors. Cell Reports, 2018, 24, 1218-1230.	6.4	27
62	Engineering of a metal coordinating site into human glutathione transferase M1-1 based on immobilized metal ion affinity chromatography of homologous rat enzymes. Protein Engineering, Design and Selection, 1994, 7, 1115-1119.	2.1	26
63	Relaxed thiol substrate specificity of glutathione transferase effected by a non-substrate glutathione derivative. FEBS Letters, 1988, 231, 155-158.	2.8	25
64	Capture and Analysis of Low Molecular Weight Ligands by Surface Plasmon Resonance Combined with Mass Spectrometry. European Journal of Mass Spectrometry, 2001, 7, 385-391.	1.0	24
65	Biotinylated lipid bilayer disks as model membranes for biosensor analyses. Analytical Biochemistry, 2010, 405, 153-159.	2.4	24
66	Kinetically Selective Inhibitors of Human Carbonic Anhydrase Isozymes I, II, VII, IX, XII, and XIII. Journal of Medicinal Chemistry, 2016, 59, 2083-2093.	6.4	23
67	Effects on protease inhibition by modifying of helicase residues in hepatitisâ€ƒC virus nonstructural proteinâ€ƒ3. FEBS Journal, 2007, 274, 5979-5986.	4.7	22
68	Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety. Bioorganic and Medicinal Chemistry, 2008, 16, 2955-2967.	3.0	22
69	Î²-Amino acid substitutions and structure-based CoMFA modeling of hepatitis C virus NS3 protease inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 5590-5605.	3.0	22
70	Introduction of Intrinsic Kinetics of Proteinâ€“Ligand Interactions and Their Implications for Drug Design. Journal of Medicinal Chemistry, 2018, 61, 2292-2302.	6.4	22
71	Cooperative effect of fructose bisphosphate and glyceraldehyde-3-phosphate dehydrogenase on aldolase action. BBA - Proteins and Proteomics, 1990, 1037, 307-312.	2.1	21
72	Biosensor-Based Screening and Characterization of HIV-1 Inhibitor Interactions with Sap 1, Sap 2, and Sap 3 from Candida albicans. Journal of Biomolecular Screening, 2006, 11, 165-175.	2.6	21

#	Article	IF	Citations
73	Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanismâ€"Importance of slow dissociation and relaxation rates for antiviral efficacy. Biochemical Pharmacology, 2010, 80, 1133-1140.	4.4	21
74	Macrocyclic Peptides Uncover a Novel Binding Mode for Reversible Inhibitors of LSD1. ACS Omega, 2020, 5, 3979-3995.	3.5	21
75	Resistance Profiling of Hepatitis C Virus Protease Inhibitors using Full-Length NS3. Antiviral Therapy, 2007, 12, 733-740.	1.0	21
76	Analysis of the pH-dependencies of the association and dissociation kinetics of HIV-1 protease inhibitors. Journal of Molecular Recognition, 2003, 16, 203-212.	2.1	20
77	Characterization of Ca2+ interactions with matrix metallopeptidase-12: implications for matrix metallopeptidase regulation. Biochemical Journal, 2006, 398, 393-398.	3.7	20
78	Probing the Kinetic Mechanism and Coenzyme Specificity of Glutathione Reductase from the CyanobacteriumAnabaenaPCC 7120 by Redesign of the Pyridine-Nucleotide-Binding Siteâ€. Biochemistry, 1999, 38, 9254-9263.	2.5	19
79	Deconstruction of Non-Nucleoside Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Type 1 for Exploration of the Optimization Landscape of Fragments. Journal of Medicinal Chemistry, 2011, 54, 709-718.	6.4	19
80	Powerful Protein Binders from Designed Polypeptides and Small Organic Moleculesâ€"A General Concept for Protein Recognition. Angewandte Chemie - International Edition, 2011, 50, 1823-1827.	13.8	19
81	Histaminergic pharmacology of homo-oligomeric Î²3 Î³-aminobutyric acid type A receptors characterized by surface plasmon resonance biosensor technology. Biochemical Pharmacology, 2012, 84, 341-351.	4.4	19
82	Achiral Pyrazinone-Based Inhibitors of the Hepatitis C Virus NS3 Protease and Drug-Resistant Variants with Elongated Substituents Directed Toward the S2 Pocket. Journal of Medicinal Chemistry, 2014, 57, 1790-1801.	6.4	19
83	HSA binding of HIV protease inhibitors: a highâ€performance affinity chromatography study. Journal of Separation Science, 2009, 32, 1625-1631.	2.5	18
84	Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents. Bioorganic and Medicinal Chemistry, 2010, 18, 5413-5424.	3.0	18
85	Development of surface plasmon resonance biosensor assays for primary and secondary screening of acetylcholine binding protein ligands. Analytical Biochemistry, 2010, 407, 58-64.	2.4	18
86	Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones. Bioorganic and Medicinal Chemistry, 2010, 18, 6512-6525.	3.0	17
87	AKAP79/150 interacts with the neuronal calciumâ€binding protein caldendrin. Journal of Neurochemistry, 2012, 122, 714-726.	3.9	17
88	Screening for NNRTIs with Slow Dissociation and High Affinity for a Panel of HIV-1 RT Variants. Journal of Biomolecular Screening, 2009, 14, 395-403.	2.6	16
89	A surface plasmon resonance-based biosensor with full-length BACE1 in a reconstituted membrane. Analytical Biochemistry, 2011, 414, 14-22.	2.4	16
90	Characterization of interactions between hepatitis C virus NS5B polymerase, annexin A2 and RNA â€“ effects on NS5B catalysis and allosteric inhibition. Virology Journal, 2017, 14, 236.	3.4	16

#	Article	IF	Citations
91	Structureâ€“activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors. Biochimica Et Biophysica Acta - General Subjects, 2004, 1672, 51-59.	2.4	15
92	Biomolecular recognition of glycosylated Î²3-peptides by GalNAc specific lectins. Journal of Molecular Recognition, 2007, 20, 132-138.	2.1	15
93	Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase. Antiviral Research, 2013, 97, 356-368.	4.1	15
94	Kinetic and mechanistic analysis of the association and dissociation of inhibitors interacting with secreted aspartic acid proteases 1 and 2 from Candida albicans. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2003, 1646, 184-195.	2.3	14
95	Let There Be Light!. Proteomes, 2016, 4, 36.	3.5	14
96	Investigation of an Allosteric Site of HIV-1 Proteinase Involved in Inhibition by Cu2+. Advances in Experimental Medicine and Biology, 1998, 436, 99-103.	1.6	14
97	The use of 5â€²-Phosphate Derivatives of Nucleoside Analogues as Inhibitors of HIV-1 Replication. Antiviral Chemistry and Chemotherapy, 1995, 6, 50-64.	0.6	13
98	Refolding of a recombinant full-length non-structural (NS3) protein from hepatitis C virus by chromatographic procedures. Biotechnology Letters, 2003, 25, 1729-1734.	2.2	13
99	Structureâ€“activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V. Antiviral Therapy, 2010, 15, 841-852.	1.0	13
100	Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2â€“P1â€² Region. ACS Medicinal Chemistry Letters, 2014, 5, 249-254.	2.8	13
101	P2â€“P1â€² macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis. Bioorganic and Medicinal Chemistry, 2011, 19, 4917-4927.	3.0	12
102	Biophysical analysis of the dynamics of calmodulin interactions with neurogranin and Ca 2+ /calmodulinâ€dependent kinase II. Journal of Molecular Recognition, 2017, 30, e2621.	2.1	12
103	Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis. Bioorganic and Medicinal Chemistry, 2007, 15, 7344-7354.	3.0	11
104	Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors. Journal of Molecular Recognition, 2011, 24, 60-70.	2.1	11
105	Quantification of interactions between drug leads and serum proteins by use of â€œbinding efficiencyâ€• Analytical Biochemistry, 2011, 409, 163-175.	2.4	11
106	Development of a novel therapeutic vaccine carrier that sustains high antibody titers against several targets simultaneously. FASEB Journal, 2017, 31, 1204-1214.	0.5	11
107	Paradoxical inhibition of rat glutathione transferase 4-4 by indomethacin explained by substrate-inhibitor-enzyme complexes in a random-order sequential mechanism. Biochemical Journal, 1988, 250, 705-711.	3.7	10
108	Sensitivity analysis and error structure of progress curves. Analytical Biochemistry, 2006, 358, 1-10.	2.4	10

#	Article	IF	Citations
109	Mechanistic studies of electrophilic protease inhibitors of full length hepatic C virus (HCV) NS3. Journal of Enzyme Inhibition and Medicinal Chemistry, 2007, 22, 191-199.	5.2	10
110	Efficient Screening of Marine Extracts for Protease Inhibitors by Combining FRET Based Activity Assays and Surface Plasmon Resonance Spectroscopy Based Binding Assays. Marine Drugs, 2013, 11, 4279-4293.	4.6	10
111	Fibrin fragment E potentiates TGF-Î²-induced myofibroblast activation and recruitment. Cellular Signalling, 2020, 72, 109661.	3.6	10
112	Resistance Profiles of Cyclic and Linear Inhibitors of HIV-1 Protease. Antiviral Chemistry and Chemotherapy, 2002, 13, 27-37.	0.6	9
113	Kinetic and mechanistic differences in the interactions between caldendrin and calmodulin with AKAP79 suggest different roles in synaptic function. Journal of Molecular Recognition, 2012, 25, 495-503.	2.1	9
114	Insights from engineering the Affibody-Fc interaction with a computational-experimental method. Protein Engineering, Design and Selection, 2017, 30, 593-601.	2.1	9
115	Estimating Detection Limits of Potentiometric DNA Sensors Using Surface Plasmon Resonance Analyses. ACS Sensors, 2020, 5, 217-224.	7.8	9
116	HIV-1 Vif-Derived Peptide Inhibits Drug-Resistant HIV Proteases. Biochemical and Biophysical Research Communications, 2002, 292, 832-840.	2.1	8
117	Detection of competitive enzyme inhibition with end point progress curve data. Analytical Biochemistry, 2006, 358, 11-19.	2.4	8
118	Hepatitis C Virus NS3 Protease Is Activated by Low Concentrations of Protease Inhibitors. Biochemistry, 2009, 48, 11592-11602.	2.5	8
119	Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 868-876.	5.2	8
120	Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase. Viruses, 2017, 9, 151.	3.3	8
121	Unveiling the Biochemistry of the Epigenetic Regulator SMYD3. Biochemistry, 2019, 58, 3634-3645.	2.5	8
122	Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase. ChemBioChem, 2021, 22, 1597-1608.	2.6	8
123	Peptide-based inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase): model compounds towards small molecule inhibitors. Bioorganic and Medicinal Chemistry, 2003, 11, 2955-2963.	3.0	7
124	The advantage of biosensor analysis over enzyme inhibition studies for slow dissociating inhibitors â€“ characterization of hydroxamate-based matrix metalloproteinase-12 inhibitors. MedChemComm, 2013, 4, 432.	3.4	7
125	Establishing Trypanosoma cruzi farnesyl pyrophosphate synthase as a viable target for biosensor driven fragmentâ€based lead discovery. Protein Science, 2020, 29, 977-989.	7.6	7
126	Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3. Antiviral Therapy, 2007, 12, 733-40.	1.0	7

#	Article	IF	Citations
127	Aliskiren displays long-lasting interactions with human renin. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 219-224.	3.0	6
128	Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease. Bioorganic and Medicinal Chemistry, 2016, 24, 2603-2620.	3.0	6
129	Synthesis ofC₂Symmetric Potential Inhibitors of HIV-1 Protease From D-Mannitol. Journal of Carbohydrate Chemistry, 1996, 15, 555-569.	1.1	5
130	Experimental and â€˜in silicoâ€™ analysis of the effect of pH on HIV-1 protease inhibitor affinity: Implications for the charge state of the protein ionogenic groups. Bioorganic and Medicinal Chemistry, 2012, 20, 4838-4847.	3.0	5
131	Pan-NS3 protease inhibitors of hepatitis C virus based on an R3-elongated pyrazinone scaffold. European Journal of Medicinal Chemistry, 2018, 148, 453-464.	5.5	5
132	Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles. Bioorganic and Medicinal Chemistry, 2014, 22, 6595-6615.	3.0	4
133	Identification of Weak Points of Hepatitis C Virus NS3 Protease Inhibitors Using Surface Plasmon Resonance Biosensor-Based Interaction Kinetic Analysis and Genetic Variants. Journal of Medicinal Chemistry, 2014, 57, 1802-1811.	6.4	4
134	Discovery of fragments inducing conformational effects in dynamic proteins using a second-harmonic generation biosensor. RSC Advances, 2021, 11, 7527-7537.	3.6	4
135	Refolding of the full-length non-structural protein 3 of hepatitis C virus. Protein Expression and Purification, 2005, 41, 298-305.	1.3	3
136	Analysis of the leakage of gene repression by an artificial TetR-regulated promoter in cyanobacteria. BMC Research Notes, 2015, 8, 459.	1.4	3
137	Specific interaction between HIV-1 proteinase and 5'-phosphate peptidomimetic derivatives of nucleoside analogues. Drug Design and Discovery, 1995, 13, 43-54.	0.3	3
138	A realâ€time cellâ€binding assay reveals dynamic features of STxBâ€“Gb3 cointernalization and STxBâ€mediated cargo delivery into cancer cells. FEBS Letters, 2020, 594, 2406-2420.	2.8	2
139	Sensitive Protein Detection Using Site-Specifically Oligonucleotide-Conjugated Nanobodies. Analytical Chemistry, 2022, 94, 10054-10061.	6.5	2
140	325 Identification and characterization of an irreversible inhibitor of CDK2. European Journal of Cancer, 2014, 50, 106.	2.8	1
141	Kinetic Analysis of Carbonic Anhydraseâ€“Sulfonamide Inhibitor Interactions. , 2019, , 125-140.		1
142	Structural Principles of Serotonin and Granisetron Recognition inÂa 5-HT3 / Binding Protein Chimera. Biophysical Journal, 2012, 102, 112a.	0.5	0
143	BRCA1 mutation site may associate with nuclear DNA content in BRCA1-associated ovarian carcinomas. Journal of Clinical Oncology, 2004, 22, 5040-5040.	1.6	0
144	Molecular Interaction Analysis for Discovery of Drugs Targeting Enzymes and for Resolving Biological Function. NATO Science for Peace and Security Series A: Chemistry and Biology, 2015, , 223-240.	0.5	0